Press Releases

Date Title and Summary
Toggle Summary Soleno Therapeutics Presents Clinical Data on DCCR at 2018 Foundation for Prader-Willi Research Annual Conference
Oral presentation on DCCR’s mechanism of action in treating hyperphagia Poster presentation on DCCR’s safety profile and implications for PWS Phase III study design REDWOOD CITY, Calif. , Oct. 08, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a clinical-stage biopharmaceutical
Toggle Summary Soleno Therapeutics Presents Clinical Data on DCCR at Late-Breaking Session of European Society for Paediatric Endocrinology
Pharmacokinetic data supports once-daily dosing Long-term use of DCCR not associated with compromised glycemic control REDWOOD CITY, Calif. , Oct. 01, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the
Toggle Summary Soleno Therapeutics to Participate in Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease
REDWOOD CITY, Calif. , Sept. 19, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar , M.D., Chief Executive Officer, will conduct
Toggle Summary Soleno Therapeutics to Present DCCR Clinical Data at Late Breaking Sessions of the European Society for Paediatric Endocrinology
REDWOOD CITY, Calif. , Sept. 17, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases will present two poster presentations from studies of Soleno’s lead product candidate,
Toggle Summary Soleno Therapeutics Announces Expansion of Ongoing Phase III Trial of DCCR in Prader-Willi Syndrome to Include Younger Patients
Amendment Lowers Minimum Age Inclusion Criteria to Four Years, from Eight Years, to Better Reflect Demographics of PWS Population Top-line Data from Phase III Trial Expected in First Half of 2019 REDWOOD CITY, Calif. , Sept. 06, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc.
Toggle Summary Soleno Therapeutics Announces Issuance of New U.S. Patent for DCCR Covering Treatment of Low Lean Body Mass in Prader-Willi Syndrome
REDWOOD CITY, Calif. , Sept. 04, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today the issuance of a new patent (No. 10/058,557) from the U.S.
Toggle Summary Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2018 Financial Results
REDWOOD CITY, Calif. , Aug. 14, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update and announced financial results for the second
Toggle Summary Soleno Therapeutics Receives Fast Track Designation from FDA for DCCR for Treatment of Prader-Willi Syndrome
Phase III Clinical Trial Ongoing at Multiple Sites in the U.S. REDWOOD CITY, Calif. , July 30, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that
Toggle Summary Soleno Therapeutics To Present Corporate Update at the BIO International Convention
REDWOOD CITY, Calif. , June 04, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar , M.D., Chief Executive Officer, will
Toggle Summary Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2018 Financial Results
REDWOOD CITY, Calif. , May 16, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update and announced financial results for the first